Sponsors (2)
Official title: Amend the Federal Food, Drug, and Cosmetic Act to establish a process for science-focused drug development meetings led by the Reagan-Udall Foundation for the Food and Drug Administration with respect to drugs for rare diseases and conditions, and for other purposes.
Introduced March 3, 2025 by Amy Klobuchar · Last progress March 3, 2025
The bill aims to speed and de-risk development of rare-disease therapies and increase transparency by creating a structured stakeholder forum, but it carries risks of industry influence, strained FDA resources, and potential approvals based on less-established evidence, with modest federal costs.
People with rare diseases: may get therapies developed and approved faster because the bill promotes alignment of trial designs, endpoints, and biomarkers across stakeholders.
Drug developers, including small biotech: gain a structured, predictable forum for early scientific discussion with the FDA and other stakeholders, potentially reducing development uncertainty, time, and costs.
Patients and clinicians: receive greater transparency since meetings and how stakeholder input affected FDA risk–benefit decisions will be documented in public transcripts, summaries, and explanations.
Patients with rare diseases: face a higher risk that approvals rely on less-established evidence if stakeholder consensus endorses novel or surrogate endpoints, which could lead to ineffective or unsafe treatments reaching the market.
Patients and the public: industry and sponsor participation on planning/steering committees creates conflict‑of‑interest risks that could bias recommendations toward sponsors' commercial interests.
FDA staff and review timelines: added meetings, participation, and reporting requirements could strain FDA review divisions and divert staff time from other regulatory review work.
Based on analysis of 2 sections of legislative text.
Requires FDA to arrange with the Reagan‑Udall Foundation to hold at least four science‑focused multi‑stakeholder meetings per year to advance rare disease drug development and align on novel development approaches.
Creates a permanent, Foundation-led process for regular, science-focused multi‑stakeholder meetings to speed and clarify development of drugs for rare diseases. The Department of Health and Human Services (FDA) must contract with the Reagan‑Udall Foundation to convene at least four meetings per year, and a standing multistakeholder steering committee will advise on topics and priorities to address scientific challenges (trial design, endpoints, biomarkers, natural history controls, manufacturing, and related issues). The goal is to align researchers, industry, clinicians, and patient groups on novel development approaches to facilitate regulatory review and approval for rare-disease therapies.